Second phase 3 study of CaPre in patients with severe hypertriglyceridemia

Trial Profile

Second phase 3 study of CaPre in patients with severe hypertriglyceridemia

Planning
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Omega-3 phospholipid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Acasti Pharma
  • Most Recent Events

    • 13 Nov 2017 According to an Acasti Pharma media release, phase 3 program is anticipated to complete in 2019.
    • 07 Nov 2017 According to an Acasti Pharma media release, Dariush Mozaffarian will be principal investigator of the phase 3 program. Acasti remains on track to begin activating sites for its Phase 3 program before the end of the year, with patient dosing expected to start in early 2018.
    • 06 Jun 2017 According to an Acasti Pharma media release, the company plans to initiate this study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top